Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Haim Erder

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|October 17, 2002
Psychological outcomes associated with anemia-related fatigue in cancer patientsJoel D Kallich, N Simon Tchekmedyian, Anne M Damiano, et al.
Pharmacoepidemiology and Drug Safety|September 27, 2014
Development and validation of algorithms to identify acute diverticulitisAniket Kawatkar, Li-Hao Chu, Rajan Iyer, et al.
Journal of Medical Economics|July 2, 2009
Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIsEric Q Wu, Paul E Greenberg, Elaine Yang, et al.
Current Medical Research and Opinion|March 29, 2011
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitorsJames Signorovitch, Karthik Ramakrishnan, Rym Ben-Hamadi, et al.
Health and Quality of Life Outcomes|November 19, 2015
Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorderKavita Gajria, Mark Kosinski, Vanja Sikirica, et al.
American Health & Drug Benefits|August 16, 2014
Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopramEric Q Wu, Paul E Greenberg, Rym Ben-Hamadi, et al.
Digestive Diseases and Sciences|January 25, 2017
PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux DiseaseGarth Fuller, Roger Bolus, Cynthia Whitman, et al.
Journal of Child and Adolescent Psychopharmacology|May 21, 2014
Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009Keith A Betts, Vanja Sikirica, Paul Hodgkins, et al.
Journal of Medical Economics|October 1, 2010
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective studyAndrew P Yu, Jipan Xie, Arielle Bensimon, et al.
The Annals of Pharmacotherapy|March 19, 2011
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorderEric Q Wu, Andrew P Yu, Veronique Lauzon, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|October 17, 2002
Psychological outcomes associated with anemia-related fatigue in cancer patientsJoel D Kallich, N Simon Tchekmedyian, Anne M Damiano, et al.
Pharmacoepidemiology and Drug Safety|September 27, 2014
Development and validation of algorithms to identify acute diverticulitisAniket Kawatkar, Li-Hao Chu, Rajan Iyer, et al.
Journal of Medical Economics|July 2, 2009
Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIsEric Q Wu, Paul E Greenberg, Elaine Yang, et al.
Current Medical Research and Opinion|March 29, 2011
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitorsJames Signorovitch, Karthik Ramakrishnan, Rym Ben-Hamadi, et al.
Health and Quality of Life Outcomes|November 19, 2015
Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorderKavita Gajria, Mark Kosinski, Vanja Sikirica, et al.
American Health & Drug Benefits|August 16, 2014
Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopramEric Q Wu, Paul E Greenberg, Rym Ben-Hamadi, et al.
Digestive Diseases and Sciences|January 25, 2017
PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux DiseaseGarth Fuller, Roger Bolus, Cynthia Whitman, et al.
Journal of Child and Adolescent Psychopharmacology|May 21, 2014
Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009Keith A Betts, Vanja Sikirica, Paul Hodgkins, et al.
Journal of Medical Economics|October 1, 2010
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective studyAndrew P Yu, Jipan Xie, Arielle Bensimon, et al.
The Annals of Pharmacotherapy|March 19, 2011
Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorderEric Q Wu, Andrew P Yu, Veronique Lauzon, et al.
Pageof 7